Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

3 weeks ago

Represents second complex respiratory therapeutic product approval in Q4 2025BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc.…

NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share

3 weeks ago

BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or “the Company”), a technology-driven company building…

TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen

3 weeks ago

ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company,…

Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting

3 weeks ago

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against…

Alkeus Pharmaceuticals Appoints Renowned Retina Specialist and Biotech Executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer

3 weeks ago

Dr. Quezada-Ruiz, an internationally recognized ophthalmologist and experienced drug development leader, has joined the company as Chief Medical Officer.Seemi Khan,…

Predictive Oncology Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement

3 weeks ago

PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a AI-driven drug discovery company that has expanded…

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

3 weeks ago

Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in heavily pretreated…

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4

3 weeks ago

HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to…